Just a month after selling a multi-million dollar boatload of stock, Coronacrapper Cytodyn (CYDY) CEO Nader “The Nadir” Pourhassan just scored a massive raise.
After the bell last night, Cytodyn issued an 8k (see here) disclosing an almost 100% increase in Nader’s base compensation to $1mm:
He wasn’t doing too badly in prior years either:
Of course on his rambling call with stock promoter Jacob Mestechkin aka Jack Marks yesterday, this was never mentioned.
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.
Like this:
Like Loading...
The big raise was voted on by a “compensation committee” that had a new director Mr. Patel that was just appointed to the board last month and was given a big mess of options, He coincidentally was named the head of the compensation committee two days before it voted to double the paycheck of the CEO who just hired him.
Correction: On May 27, 2020, the Board appointed Dr. Patel to the Board’s Nominating and Governance Committee as its chair.
Some additional paid publications touting Cytodyn:
Futuremoneytrends.com
Insiderfinancial.com
microcapdaily.com
biopharmajournal.com
An interesting microcap IR agency with many questionable biotechs (but not Cytodyn):
Acorn Management Partners, LLC
Yeah every single DR. That has used Leronlimab. Is a lying con artist and not to be believed. They would all risk their careers for Nader? You’re an idiot.
[You are clearly unfamiliar with how clinical trials work. Doctors and hospitals are paid by the sponsor, in this case Cytodyn. They are not risking anything. – Editor]